Yahoo Web Search

Search results

    • Two Is Better Than One in the Alzheimer’s Market

      Two Is Better Than One in the Alzheimer’s Market

      The Wall Street Journal via Yahoo Finance· 14 hours ago

      That might be the case for midsize biotech Biogen and its Japanese partner Eisai. Their Alzheimer’s drug, Leqembi, was approved by the Food...

    • ‘We have been clear’ … or have you?

      ‘We have been clear’ … or have you?

      Politico· 6 days ago

      Sepp noted that his country, widely viewed as one of the most advanced nations in cybersecurity globally, also advised the Japanese government on...